den senaste versionen av TNM ger prognostisk information till patienter med SCLC samt medför bättre subgruppering av patienter med olika tumörbörda i jämförelse med tidigare klassifikationssystem. Därför anser vi att den 8:e TNM-versionen bör vara standard för klassificering av patienter med SCLC i framtiden.

Long-term cancer survivors are at 13% increased risk of mood disorders particularly in the first 2 years after diagnosis. The depression risk indicate the need of psychological care.

Lungcancerkirurgi

Postoperativ IMT som komplement till sedvanlig fysioterapi som omfattar tidig mobilisering kan förebygga en möjlig minskning av den fysiska aktivitetsnivån två veckor efter kirurgi bland patienter med hög risk för utveckling av postoperativa lungkomplikationer efter lungcancerkirurgi.

MEST SETE MEDtalks

Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)   Se hele webinar

Smouldering myeloma and high risk patients – a close look at GEM-CESAR and CENTAURUS studies (1:3)

<script src="https://fast.wistia.com/embed/medias/8r1j245h32.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8r1j245h32 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8r1j245h32/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/smouldering-myeloma-and-high-risk-patients-a-close-look-at-gem-cesar-and-centaurus-studies-13/'>Se hele webinar
Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)

Uppseendeväckande resultat om behandling av myelomatos

<script src="https://fast.wistia.com/embed/medias/eghvlbohui.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eghvlbohui videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/eghvlbohui/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Uppseendeväckande resultat om behandling av myelomatos
Uppseendeväckande resultat om behandling av myelomatos

ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice

<img width="600" height="360" src="https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play-600x360.jpg" class="attachment-category_newDes_thumb_1 size-category_newDes_thumb_1 wp-post-image" alt="" srcset="https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play-600x360.jpg 600w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play-300x179.jpg 300w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play-768x459.jpg 768w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play-1024x612.jpg 1024w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play-360x215.jpg 360w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/timothy-devos_play.jpg 1200w" sizes="(max-width: 600px) 100vw, 600px" />
ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/ash-2018-efficacy-and-safety-of-ponatinib-in-cml-and-ph-all-patients-in-real-world-clinical-practice/'>Se hele webinar
ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice

ASH 2018: Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL. Update data from MURANO study

<img width="600" height="360" src="https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play-600x360.jpg" class="attachment-category_newDes_thumb_1 size-category_newDes_thumb_1 wp-post-image" alt="" srcset="https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play-600x360.jpg 600w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play-300x179.jpg 300w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play-768x459.jpg 768w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play-1024x612.jpg 1024w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play-360x215.jpg 360w, https://bestprac.se/wp-content/uploads/sites/3/2018/12/john-f-seymour_play.jpg 1200w" sizes="(max-width: 600px) 100vw, 600px" />
ASH 2018: Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL. Update data from MURANO study&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/ash-2018-venetoclax-rituximab-combination-therapy-in-relapsed-refractory-cll-update-data-from-murano-study/'>Se hele webinar
ASH 2018: Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL. Update data from MURANO study

Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in 20-30% of patients with advanced melanoma, and non-small cell lung cancer (NSCLC).1  However, there is a need for the identification of biomarkers that may predict response or are modulated during the course of immune-based therapy. Biomarkers predictive of response: an urgent need in the field The majority of the tested biomarkers are based on immunohistochemistry for protein detection or flow cytometry analysis for identification of the relevant cell populations.2 However, a few whole-exome -sequencing studies in tumor sections have revealed that the mutational burden sensitizes to PD-1 blockade in NSCLC, and that this burden can be originated by somatic genetic mutations in the mismatch repair genes.3…

Diagnostiken av prostatacancer är under snabb utveckling. Projektet STHLM3MR undersöker hur en kombination av nya blodprov och MR-undersökning med riktad biopsi presterar jämfört med traditionell diagnostik. Resultat visar att användande av Stockholm3-testet och MR-riktade biopsier ökar detektionen av signifikant cancer samtidigt som det minskar överdiagnostik och antal prostatabiopsier.

Metastasering är den främsta orsaken till cancerdödlighet, och koloncancer är en av de mest invasiva och spridningsbenägna tumörformerna. Således är det väldigt viktigt och bråttom att utveckla cancermediciner för att minska cancercellernas spridning.

#Senaste Tidskrifter

Onkologi / Hematologi

NR. 4 • september 2018
Årgång 2
  • EHA 2018
  • Prostatacancer
  • Bröstcancerrisk

ASH 2018

EHA 2018

#

Onkologi / Hematologi

Vladimir Lazarevic,

Vladimir Lazarevic,
överläkare

Hareth Nahi

Hareth Nahi
med.dr, fil.dr